Dyslipidemie

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

What is PRALUENT®?

PRALUENT^®: a powerful PCSK9i that ticks all the boxes^1–4

PRALUENT is available as a unique,¥ once-monthly pen

Praluent: artsenverklaring

Praluent Zorgservice

Praluent: peninstructie video's

In de video's wordt duidelijk uitgelegd hoe de pen te gebruiken - voor beide doseringen.

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262